콘텐츠로 건너뛰기
Merck
  • Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma.

Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma.

Biochemical and biophysical research communications (2009-03-03)
Paul Gutwein, Anja Schramme, Beren Voss, Mohamed Sadek Abdel-Bakky, Kai Doberstein, Andreas Ludwig, Peter Altevogt, Martin-Leo Hansmann, Holger Moch, Glen Kristiansen, Josef Pfeilschifter
초록

Junctional adhesion molecule-A (JAM-A) is one component of tight junctions which are involved in important processes like paracellular permeability, cell polarity, adhesion, migration, and angiogenesis. Here we describe JAM-A expression in distal convoluted tubule, connecting tubule, and in cells of the collecting duct of the healthy human kidney. In addition, JAM-A was weakly expressed in cells of the proximal tubule. Using immunofluorescence, FACS and Western blot analysis we investigated JAM-A expression in tubular cells in vitro. Interestingly, treatment of HK-2 cells with IFN-gamma and TNF-alpha resulted in a metalloproteinase mediated downregulation of JAM-A. Importantly, in a tissue micro-array JAM-A protein expression was significantly downregulated in patients with clear cell renal cell carcinoma. Furthermore, knockdown of JAM-A with JAM-A specific siRNA induced the migration of RCC4 cells. In summary, downregulation of JAM-A is an early event in the development of renal cancer and increases the migration of renal cancer cells.